Odanacatib

Phase 3Small molecule

Merck & Co.

Odanacatib is one of 105 small molecule programs targeting Bone Metastasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasisActive, not recruiting

Postmenopausal OsteoporosisActive, not recruiting

Breast CancerActive, not recruiting

OsteoporosisActive, not recruiting

Bone MetastasisPhase 3

Active, not recruiting

Postmenopausal OsteoporosisPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

OsteoporosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Odanacatib

Merck & Co.

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Women4 trials

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01803607·135 enrolled

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 3·NCT01552122

A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00885170·246 enrolled

Show 1 more trial

Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00729183·214 enrolled

Osteoporosis3 trials

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01120600·294 enrolled

Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00620113·287 enrolled

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00529373·16,071 enrolled

Tics2 trials

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00863525·8 enrolled

A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00863590·24 enrolled

Breast Cancer1 trial

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00399802·43 enrolled

Glucocorticoids1 trial

A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01630616·19 enrolled

5 more indications

Female1 trial

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00770159·78 enrolled

Postmenopausal Osteoporosis1 trial

A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00112437·399 enrolled

Adult1 trial

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00769418·62 enrolled

Bone Metastasis1 trial

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 3·NCT00691899

NAC1 trial

Safety and Tolerability of Odanacatib (0822-059)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01068262·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Odanacatib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Odanacatib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Odanacatib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Odanacatib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Women4 trials

Osteoporosis3 trials

Tics2 trials

Breast Cancer1 trial

Glucocorticoids1 trial

Female1 trial

Postmenopausal Osteoporosis1 trial

Adult1 trial

Bone Metastasis1 trial

NAC1 trial

References

Drug Info

Quick Facts

Related News